Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07396324 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

Study acronym: NEO-ITHRAN
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment openedv2 Show 4 more changesShow less
    • Start date changed from estimate of Mar 2026 to May 1, 2026
    • Interventions: Carboplatin (Drug), Iparomlimab and Tuvonralimab (QL1706) (Drug), Paclitaxel (Drug) to Carboplatin (Drug), Iparomlimab and Tuvonralimab (Drug), Paclitaxel (Drug)
    • Site details revised
    • Study title shortened, about 3 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RenJi Hospital
190 trials monitored
See 2 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Trial Details
NCT Number NCT07396324
Lead Sponsor RenJi Hospital
Conditions
(from sponsor)		 HR-positive/HER2-negative Breast Cancer
Enrollment 55 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov